XiaoXia Wei (Xiaoxia Wei)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Topics

Early Breast Cancer

Endoplasmic Reticulum

Estrogen Receptor

Ejection Fraction

Top Venues

Clinical drug investigation

International journal of clinical pharmacy

Scientific reports

International journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

LiRong Zhang, Jiaqin Cai, Huiting Lin, Wenhua Wu, Congting Hu, Xinmiao Lin, Hong Sun, XiaoXia Wei
SGLT-2 inhibitors are beneficial in reducing the risk of thyroid cancer: findings from a Mendelian randomization study. Acta diabetologica (2024)
Yingdan Cao, Hongbin Yi, Fenghao Shi, XiaoXia Wei, Sheng Han
Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States. International journal of clinical pharmacy (2024)
Wenhua Wu, Huiting Lin, Jiaqin Cai, Hong Sun, Jia Liu, Congting Hu, XiaoXia Wei
Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA? Clinical drug investigation (2023)
XiaoXia Wei, Jing Zhuang, Na Li, Bin Zheng, Hong Sun, JiaQin Cai, Xuhui Huang, Guifeng Zhang, Jie Zhuang
NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China. International journal of hematology (2021)
Dangdi Liang, Ahmed Fathy Yousef, XiaoXia Wei, Muhammad Moaaz Ali, Weijun Yu, Liuqing Yang, Ralf Oelmüller, Faxing Chen
Increasing the performance of Passion fruit (Passiflora edulis) seedlings by LED light regimes. Scientific reports 11 (1) (2021)
XiaoXia Wei, Hong Sun, Jie Zhuang, Xiuhua Weng, Bin Zheng, Qiwang Lin, Guifeng Zhang, Jiaqin Cai
Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China. Clinical drug investigation 40 (1) (2020)